Dr Diana Hernandez, director of immune and advanced therapies at Anthony Nolan, said: “NK cells have huge potential as off-the-shelf therapies, and this trial takes us one step closer to a wider application of engineered NK cells in the targeted treatment of cancers.
“NK cells from healthy donors could provide new hope for patients like Tracy who have run out of treatment options. At Anthony Nolan we have long seen the potential of cellular therapies like this to transform the lives of patients with blood cancer.
“Today’s research represents exciting progress for patients with solid tumours to benefit from these promising therapies.”
Contact details are available to account holders.
Create a free account to get in touch with this expert.